Immatics Biotechnologies' Series D Round

Immatics Biotechnologies raised a round of funding on October 15, 2013.

immatics biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. immatics' lead product, IMA901, is in a pivot…

Articles about Immatics Biotechnologies' Series D Round: